Medpace Holdings, Inc.

NasdaqGS:MEDP Rapporto sulle azioni

Cap. di mercato: US$12.0b

La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Medpace Holdings Gestione

Gestione criteri di controllo 4/4

Medpace Holdings' Il CEO è August Troendle, nominato in Jul1992, e ha un mandato di 32.08 anni. la retribuzione annua totale è $ 1.65M, composta da 49.5% di stipendio e 50.5% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 17.42% delle azioni della società, per un valore di $ 2.10B. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 5.5 anni e 6 anni.

Informazioni chiave

August Troendle

Amministratore delegato

US$1.6m

Compenso totale

Percentuale dello stipendio del CEO49.5%
Mandato del CEO32.1yrs
Proprietà del CEO17.4%
Durata media del management5.5yrs
Durata media del Consiglio di amministrazione6yrs

Aggiornamenti recenti sulla gestione

Recent updates

Medpace: Continued Business Growth With Asymmetrical Payoff Opportunity

Aug 20

Why Medpace Holdings' (NASDAQ:MEDP) Earnings Are Better Than They Seem

Jul 31
Why Medpace Holdings' (NASDAQ:MEDP) Earnings Are Better Than They Seem

Medpace Holdings, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Jul 25
Medpace Holdings, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

What You Can Learn From Medpace Holdings, Inc.'s (NASDAQ:MEDP) P/E

Jun 18
What You Can Learn From Medpace Holdings, Inc.'s (NASDAQ:MEDP) P/E

Medpace: Clear Winner If China Blockade Succeeds

Jun 04

A Look At The Fair Value Of Medpace Holdings, Inc. (NASDAQ:MEDP)

May 22
A Look At The Fair Value Of Medpace Holdings, Inc. (NASDAQ:MEDP)

Does Medpace Holdings (NASDAQ:MEDP) Deserve A Spot On Your Watchlist?

Apr 12
Does Medpace Holdings (NASDAQ:MEDP) Deserve A Spot On Your Watchlist?

Medpace: Exceptional Performance, Almost Fully Priced In

Mar 11

Medpace Holdings, Inc.'s (NASDAQ:MEDP) 32% Jump Shows Its Popularity With Investors

Feb 18
Medpace Holdings, Inc.'s (NASDAQ:MEDP) 32% Jump Shows Its Popularity With Investors

Should You Think About Buying Medpace Holdings, Inc. (NASDAQ:MEDP) Now?

Feb 09
Should You Think About Buying Medpace Holdings, Inc. (NASDAQ:MEDP) Now?

A Look At The Intrinsic Value Of Medpace Holdings, Inc. (NASDAQ:MEDP)

Jan 25
A Look At The Intrinsic Value Of Medpace Holdings, Inc. (NASDAQ:MEDP)

Should You Be Adding Medpace Holdings (NASDAQ:MEDP) To Your Watchlist Today?

Jan 10
Should You Be Adding Medpace Holdings (NASDAQ:MEDP) To Your Watchlist Today?

Shareholders Should Be Pleased With Medpace Holdings, Inc.'s (NASDAQ:MEDP) Price

Dec 26
Shareholders Should Be Pleased With Medpace Holdings, Inc.'s (NASDAQ:MEDP) Price

Should You Investigate Medpace Holdings, Inc. (NASDAQ:MEDP) At US$275?

Nov 08
Should You Investigate Medpace Holdings, Inc. (NASDAQ:MEDP) At US$275?

Medpace Holdings, Inc. (NASDAQ:MEDP) Shares Could Be 29% Below Their Intrinsic Value Estimate

Oct 23
Medpace Holdings, Inc. (NASDAQ:MEDP) Shares Could Be 29% Below Their Intrinsic Value Estimate

If EPS Growth Is Important To You, Medpace Holdings (NASDAQ:MEDP) Presents An Opportunity

Oct 10
If EPS Growth Is Important To You, Medpace Holdings (NASDAQ:MEDP) Presents An Opportunity

Does Medpace Holdings (NASDAQ:MEDP) Have A Healthy Balance Sheet?

Aug 27
Does Medpace Holdings (NASDAQ:MEDP) Have A Healthy Balance Sheet?

Should You Think About Buying Medpace Holdings, Inc. (NASDAQ:MEDP) Now?

Jul 31
Should You Think About Buying Medpace Holdings, Inc. (NASDAQ:MEDP) Now?

A Look At The Fair Value Of Medpace Holdings, Inc. (NASDAQ:MEDP)

Jul 18
A Look At The Fair Value Of Medpace Holdings, Inc. (NASDAQ:MEDP)

Here's Why We Think Medpace Holdings (NASDAQ:MEDP) Might Deserve Your Attention Today

Jul 04
Here's Why We Think Medpace Holdings (NASDAQ:MEDP) Might Deserve Your Attention Today

Is Medpace Holdings (NASDAQ:MEDP) A Risky Investment?

May 25
Is Medpace Holdings (NASDAQ:MEDP) A Risky Investment?

Is Now The Time To Look At Buying Medpace Holdings, Inc. (NASDAQ:MEDP)?

Apr 27
Is Now The Time To Look At Buying Medpace Holdings, Inc. (NASDAQ:MEDP)?

An Intrinsic Calculation For Medpace Holdings, Inc. (NASDAQ:MEDP) Suggests It's 28% Undervalued

Apr 12
An Intrinsic Calculation For Medpace Holdings, Inc. (NASDAQ:MEDP) Suggests It's 28% Undervalued

We Ran A Stock Scan For Earnings Growth And Medpace Holdings (NASDAQ:MEDP) Passed With Ease

Mar 27
We Ran A Stock Scan For Earnings Growth And Medpace Holdings (NASDAQ:MEDP) Passed With Ease

Does Medpace Holdings (NASDAQ:MEDP) Have A Healthy Balance Sheet?

Feb 14
Does Medpace Holdings (NASDAQ:MEDP) Have A Healthy Balance Sheet?

What Is Medpace Holdings, Inc.'s (NASDAQ:MEDP) Share Price Doing?

Jan 16
What Is Medpace Holdings, Inc.'s (NASDAQ:MEDP) Share Price Doing?

Medpace Holdings, Inc. (NASDAQ:MEDP) Shares Could Be 41% Below Their Intrinsic Value Estimate

Jan 03
Medpace Holdings, Inc. (NASDAQ:MEDP) Shares Could Be 41% Below Their Intrinsic Value Estimate

Here's Why We Think Medpace Holdings (NASDAQ:MEDP) Might Deserve Your Attention Today

Dec 20
Here's Why We Think Medpace Holdings (NASDAQ:MEDP) Might Deserve Your Attention Today

Medpace Holdings (NASDAQ:MEDP) Has A Rock Solid Balance Sheet

Nov 16
Medpace Holdings (NASDAQ:MEDP) Has A Rock Solid Balance Sheet

Growth Investors: Industry Analysts Just Upgraded Their Medpace Holdings, Inc. (NASDAQ:MEDP) Revenue Forecasts By 13%

Nov 03
Growth Investors: Industry Analysts Just Upgraded Their Medpace Holdings, Inc. (NASDAQ:MEDP) Revenue Forecasts By 13%

Why Medpace Holdings, Inc. (NASDAQ:MEDP) Could Be Worth Watching

Oct 10
Why Medpace Holdings, Inc. (NASDAQ:MEDP) Could Be Worth Watching

Medpace Holdings, Inc. (NASDAQ:MEDP) Shares Could Be 33% Below Their Intrinsic Value Estimate

Sep 26
Medpace Holdings, Inc. (NASDAQ:MEDP) Shares Could Be 33% Below Their Intrinsic Value Estimate

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di August Troendle rispetto agli utili di Medpace Holdings?
DataCompenso totaleStipendioGuadagni aziendali
Jun 30 2024n/an/a

US$340m

Mar 31 2024n/an/a

US$312m

Dec 31 2023US$2mUS$814k

US$283m

Sep 30 2023n/an/a

US$273m

Jun 30 2023n/an/a

US$268m

Mar 31 2023n/an/a

US$257m

Dec 31 2022US$2mUS$770k

US$245m

Sep 30 2022n/an/a

US$227m

Jun 30 2022n/an/a

US$209m

Mar 31 2022n/an/a

US$199m

Dec 31 2021US$6mUS$697k

US$181m

Sep 30 2021n/an/a

US$182m

Jun 30 2021n/an/a

US$175m

Mar 31 2021n/an/a

US$159m

Dec 31 2020US$4mUS$608k

US$145m

Sep 30 2020n/an/a

US$124m

Jun 30 2020n/an/a

US$107m

Mar 31 2020n/an/a

US$110m

Dec 31 2019US$8mUS$504k

US$100m

Sep 30 2019n/an/a

US$93m

Jun 30 2019n/an/a

US$88m

Mar 31 2019n/an/a

US$78m

Dec 31 2018US$528kUS$420k

US$73m

Sep 30 2018n/an/a

US$61m

Jun 30 2018n/an/a

US$52m

Mar 31 2018n/an/a

US$45m

Dec 31 2017US$598kUS$419k

US$39m

Compensazione vs Mercato: La retribuzione totale di August ($USD 1.65M ) è inferiore alla media delle aziende di dimensioni simili nel mercato US ($USD 13.17M ).

Compensazione vs guadagni: La retribuzione di August è stata coerente con le performance aziendali dell'ultimo anno.


AMMINISTRATORE DELEGATO

August Troendle (68 yo)

32.1yrs

Mandato

US$1,646,031

Compensazione

Dr. August James Troendle, M.D. serves as Chairman of CinRx Pharma, LLC. He has been the Chairman, Chief Executive Officer at Medpace Holdings, Inc. since July 1992 and served as its President since July 1...


Gruppo dirigente

NomePosizioneMandatoCompensazioneProprietà
August Troendle
Chairman & CEO32.1yrsUS$1.65m17.42%
$ 2.1b
Jesse Geiger
President3yrsUS$945.08k0.070%
$ 8.4m
Kevin Brady
CFO & Treasurer5.5yrsUS$690.48k0.019%
$ 2.3m
Susan Burwig
Executive Vice President of Operations7.6yrsUS$1.12m0.19%
$ 22.4m
Stephen Ewald
Chief Compliance Officer12.2yrsUS$914.64k0.043%
$ 5.2m
Brandon Ebken
Chief Information Officer3.6yrsNessun datoNessun dato
Lauren Morris
Associate Director of Investors Relationsno dataNessun datoNessun dato
Todd Meyers
Vice President of Business Development & Marketingno dataNessun datoNessun dato
John Wynne
Senior Vice President of Commercial Operations & Clinical Pharmacology Unitno dataNessun datoNessun dato
Reinilde Heyrman
Chief Medical Officer of Medical Department1.6yrsNessun datoNessun dato
Gina Leisring
Senior Vice President of Clinical Monitoringno dataNessun datoNessun dato

5.5yrs

Durata media

58yo

Età media

Gestione esperta: Il team dirigenziale di MEDP è esperto e expertise (durata media dell'incarico 5.5 anni).


Membri del Consiglio di amministrazione

NomePosizioneMandatoCompensazioneProprietà
August Troendle
Chairman & CEO32.1yrsUS$1.65m17.42%
$ 2.1b
Fred Davenport
Lead Independent Director6yrsUS$264.98k0.0065%
$ 779.2k
Cornelius McCarthy
Independent Director6yrsUS$217.48k0.017%
$ 2.0m
Robert Kraft
Independent Director8.1yrsUS$227.35k0.0017%
$ 202.3k
Brian Carley
Independent Director8.1yrsUS$234.97k0.070%
$ 8.5m
Femida Gwadry-Sridhar
Independent Director1.6yrsUS$258.37k0%
$ 0
Dani Zander
Directorless than a yearNessun datoNessun dato

6.0yrs

Durata media

66yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di MEDP sono considerati esperti (durata media dell'incarico 6 anni).